S&P 500   4,515.11 (+0.64%)
DOW   35,437.59 (+0.51%)
QQQ   374.80 (+0.58%)
AAPL   148.49 (+1.32%)
MSFT   308.15 (+0.28%)
FB   339.36 (+1.20%)
GOOGL   2,856.89 (+0.05%)
TSLA   869.99 (-0.01%)
AMZN   3,424.05 (-0.66%)
NVDA   223.16 (+0.42%)
BABA   173.55 (+4.03%)
NIO   40.09 (+1.21%)
CGC   13.51 (+2.35%)
GE   104.78 (+0.63%)
AMD   116.99 (+0.48%)
MU   67.25 (-0.01%)
T   25.44 (+0.43%)
F   15.57 (+0.06%)
ACB   6.96 (+0.58%)
DIS   170.45 (-0.40%)
PFE   42.05 (+1.77%)
BA   216.14 (-0.39%)
AMC   42.68 (-0.81%)
S&P 500   4,515.11 (+0.64%)
DOW   35,437.59 (+0.51%)
QQQ   374.80 (+0.58%)
AAPL   148.49 (+1.32%)
MSFT   308.15 (+0.28%)
FB   339.36 (+1.20%)
GOOGL   2,856.89 (+0.05%)
TSLA   869.99 (-0.01%)
AMZN   3,424.05 (-0.66%)
NVDA   223.16 (+0.42%)
BABA   173.55 (+4.03%)
NIO   40.09 (+1.21%)
CGC   13.51 (+2.35%)
GE   104.78 (+0.63%)
AMD   116.99 (+0.48%)
MU   67.25 (-0.01%)
T   25.44 (+0.43%)
F   15.57 (+0.06%)
ACB   6.96 (+0.58%)
DIS   170.45 (-0.40%)
PFE   42.05 (+1.77%)
BA   216.14 (-0.39%)
AMC   42.68 (-0.81%)
S&P 500   4,515.11 (+0.64%)
DOW   35,437.59 (+0.51%)
QQQ   374.80 (+0.58%)
AAPL   148.49 (+1.32%)
MSFT   308.15 (+0.28%)
FB   339.36 (+1.20%)
GOOGL   2,856.89 (+0.05%)
TSLA   869.99 (-0.01%)
AMZN   3,424.05 (-0.66%)
NVDA   223.16 (+0.42%)
BABA   173.55 (+4.03%)
NIO   40.09 (+1.21%)
CGC   13.51 (+2.35%)
GE   104.78 (+0.63%)
AMD   116.99 (+0.48%)
MU   67.25 (-0.01%)
T   25.44 (+0.43%)
F   15.57 (+0.06%)
ACB   6.96 (+0.58%)
DIS   170.45 (-0.40%)
PFE   42.05 (+1.77%)
BA   216.14 (-0.39%)
AMC   42.68 (-0.81%)
S&P 500   4,515.11 (+0.64%)
DOW   35,437.59 (+0.51%)
QQQ   374.80 (+0.58%)
AAPL   148.49 (+1.32%)
MSFT   308.15 (+0.28%)
FB   339.36 (+1.20%)
GOOGL   2,856.89 (+0.05%)
TSLA   869.99 (-0.01%)
AMZN   3,424.05 (-0.66%)
NVDA   223.16 (+0.42%)
BABA   173.55 (+4.03%)
NIO   40.09 (+1.21%)
CGC   13.51 (+2.35%)
GE   104.78 (+0.63%)
AMD   116.99 (+0.48%)
MU   67.25 (-0.01%)
T   25.44 (+0.43%)
F   15.57 (+0.06%)
ACB   6.96 (+0.58%)
DIS   170.45 (-0.40%)
PFE   42.05 (+1.77%)
BA   216.14 (-0.39%)
AMC   42.68 (-0.81%)
NASDAQ:ATRA

Atara Biotherapeutics News Headlines

$14.68
-0.02 (-0.14 %)
(As of 10/19/2021 11:37 AM ET)
Add
Compare
Today's Range
$14.44
$14.81
50-Day Range
$11.99
$17.98
52-Week Range
$11.81
$28.20
Volume7,206 shs
Average Volume854,331 shs
Market Capitalization$1.24 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.27

Media Mentions By Week

Atara Biotherapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ATRA
News Sentiment

0.00

0.36

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ATRA Articles
This Week

6

1

ATRA Articles
Average Week

Get Atara Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.

Atara Biotherapeutics (NASDAQ ATRA) News Headlines Today

SourceHeadline
marketbeat.com logoAtara Biotherapeutics (NASDAQ:ATRA) Now Covered by Mizuho
marketbeat.com - October 13 at 12:32 PM
MarketBeat logoAtara Biotherapeutics (NASDAQ:ATRA) Stock Price Down 10.6%
americanbankingnews.com - October 13 at 1:46 PM
MarketBeat logoAtara Biotherapeutics (NASDAQ:ATRA) Now Covered by Analysts at Mizuho
americanbankingnews.com - October 13 at 12:26 PM
finance.yahoo.com logoAtara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
finance.yahoo.com - October 13 at 8:06 AM
MarketBeat logoZacks: Analysts Expect Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to Post -$0.92 Earnings Per Share
americanbankingnews.com - October 9 at 7:06 PM
MarketBeat logoHC Wainwright Reaffirms "Buy" Rating for Atara Biotherapeutics (NASDAQ:ATRA)
americanbankingnews.com - October 5 at 12:48 PM
MarketBeat logoAtara Biotherapeutics (NASDAQ:ATRA) PT Lowered to $27.00
americanbankingnews.com - October 4 at 5:14 PM
businesswire.com logoAtara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel ®)
businesswire.com - October 4 at 8:44 AM
finance.yahoo.com logoAtara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
finance.yahoo.com - October 4 at 8:44 AM
MarketBeat logoAtara Biotherapeutics (NASDAQ:ATRA) Shares Gap Up to $17.90
americanbankingnews.com - October 1 at 10:50 AM
finance.yahoo.com logoWe're Not Very Worried About Atara Biotherapeutics' (NASDAQ:ATRA) Cash Burn Rate
finance.yahoo.com - October 1 at 7:41 AM
MarketBeat logoMizuho Initiates Coverage on Atara Biotherapeutics (NASDAQ:ATRA)
americanbankingnews.com - September 29 at 1:00 PM
finance.yahoo.com logoAtara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
finance.yahoo.com - September 29 at 5:04 AM
MarketBeat logoAtara Biotherapeutics (NASDAQ:ATRA) Shares Up 2.9%
americanbankingnews.com - September 28 at 1:34 PM
markets.businessinsider.com logoAtara: EMA Grants Accelerated Assessment To Tab-cel - Quick Facts
markets.businessinsider.com - September 27 at 9:34 AM
finance.yahoo.com logoEuropean Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
finance.yahoo.com - September 27 at 9:34 AM
finance.yahoo.com logoAtara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
finance.yahoo.com - September 2 at 10:11 AM
finance.yahoo.com logoAtara Biotherapeutics, inc (ATRA) Q2 2021 Earnings Call Transcript
finance.yahoo.com - August 17 at 2:37 AM
seekingalpha.com logoAtara Biotherapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation
seekingalpha.com - August 10 at 7:08 AM
finance.yahoo.com logoAtara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 9 at 7:48 PM
finance.yahoo.com logoAtara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors
finance.yahoo.com - August 9 at 6:06 PM
finance.yahoo.com logoAtara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
finance.yahoo.com - August 9 at 6:06 PM
finance.yahoo.com logoAtara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
finance.yahoo.com - August 2 at 9:04 AM
nasdaq.com logoAtara Biotherapeutics, Inc. Common Stock (ATRA)
nasdaq.com - July 28 at 11:41 PM
finance.yahoo.com logoIs Atara Biotherapeutics Inc (ATRA) A Good Stock To Buy?
finance.yahoo.com - July 21 at 12:39 PM
finance.yahoo.com logoAtara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers
finance.yahoo.com - July 1 at 8:08 PM
nasdaq.com logoSVP & Chief Commercial Officer Kristin Yarema Just Bought 165% More Shares In Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
nasdaq.com - June 18 at 8:32 AM
finance.yahoo.com logoKristin Yarema Is The SVP & Chief Commercial Officer of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) And They Just Picked Up 165% More Shares
finance.yahoo.com - June 18 at 8:32 AM
nasdaq.com logoWednesday 6/16 Insider Buying Report: CORT, ATRA
nasdaq.com - June 16 at 1:48 PM
finance.yahoo.com logoAtara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect
finance.yahoo.com - June 7 at 2:19 PM
nasdaq.com logoIf You Had Bought Atara Biotherapeutics' (NASDAQ:ATRA) Shares Three Years Ago You Would Be Down 71%
nasdaq.com - June 6 at 1:45 PM
finance.yahoo.com logoWould Shareholders Who Purchased Atara Biotherapeutics' (NASDAQ:ATRA) Stock Three Years Be Happy With The Share price Today?
finance.yahoo.com - May 20 at 9:29 AM
finance.yahoo.com logoJ.P. Morgan: These 2 Stocks Could Yield Big Returns in the Coming Year
finance.yahoo.com - May 19 at 5:56 PM
finance.yahoo.com logoAtara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit
finance.yahoo.com - May 14 at 2:01 AM
finance.yahoo.com logoAtara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer
finance.yahoo.com - May 10 at 9:31 AM
msn.com logoAtara Biotherapeutics Inc (ATRA) Q1 2021 Earnings Call Transcript
msn.com - May 5 at 8:24 AM
finance.yahoo.com logoAtara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 4 at 9:08 PM
finance.yahoo.com logoAtara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress
finance.yahoo.com - May 4 at 4:08 PM
finance.yahoo.com logoAtara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021
finance.yahoo.com - April 27 at 6:38 PM
finance.yahoo.com logoIs ATRA Stock A Buy or Sell?
finance.yahoo.com - April 26 at 1:43 AM
nasdaq.com logoHere's Why We're Not Too Worried About Atara Biotherapeutics' (NASDAQ:ATRA) Cash Burn Situation
nasdaq.com - April 7 at 5:51 PM
nasdaq.com logoAtara Biotherapeutics Becomes Oversold (ATRA)
nasdaq.com - March 26 at 12:52 PM
finance.yahoo.com logoWe're Hopeful That Atara Biotherapeutics (NASDAQ:ATRA) Will Use Its Cash Wisely
finance.yahoo.com - March 21 at 12:42 PM
businesswire.com logoAtara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel ® Studies for Epstein-Barr Virus-Driven Post-Transplant ...
businesswire.com - March 14 at 5:11 PM
finance.yahoo.com logoAtara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting
finance.yahoo.com - March 14 at 5:11 PM
finance.yahoo.com logoAtara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference
finance.yahoo.com - March 9 at 6:06 PM
nasdaq.com logoAtara Biotherapeutics Breaks Below 200-Day Moving Average - Notable for ATRA
nasdaq.com - March 5 at 8:03 AM
finance.yahoo.com logoAtara Biotherapeutics Inc (ATRA) Q4 2020 Earnings Call Transcript
finance.yahoo.com - March 2 at 9:43 AM
seekingalpha.com logoAtara Biotherapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - March 1 at 7:09 PM
finance.yahoo.com logoAtara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
finance.yahoo.com - March 1 at 6:24 PM
finance.yahoo.com logoAtara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021
finance.yahoo.com - February 18 at 4:29 PM
Get Atara Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/19/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.